Enhanced immunosuppression induced by targeted mutation of cytotoxic T lymphocyte antigen 4-immunoglobulin

Current Opinion in Organ Transplantation

Volumn 10, Issue 4, 2005, Pages 265-269

  Kokko, Kenneth E ^a   Newell, Kenneth A ^a   Pearson, Thomas C ^a   Larsen, Christian P ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

CD154; CD28; CD40; Rejection; T cell costimulation; Transplantation

Indexed keywords

B7 ANTIGEN; BELATACEPT; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEA 29 Y; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ANTIBODY PRODUCTION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 28044462615     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000186082.47623.76     Document Type: Review

References (40)

1. U.S. Organ Procurement and Transplantation Network and the Scientific Registry for Transplant Recipients. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry for Transplant Recipients: Transplant Data 1994-2003. Edited by: Department of Health and Human Services Health Resources and Services Administration, Health Care Systems Bureau, Division of Transplantation. Rockville, MD: United Network for Organ Sharing; Richmond, VA: University Renal Research and Education Association; Ann Arbor, MI: 2004.
2. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4:1289-1295.
3. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3:178-185.
4. Bostom AD, Brown RS Jr, Chavers BM, et al. Prevention of post-transplant cardiovascular disease: report and recommendations of an ad hoc group. Am J Transplant 2002; 2:491-500.
5. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333.
6. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
7. Greenwald RJ, Freeman GJ, Sharpe AH. The B 7 family revisited. Annu Rev Immunol 2005; 23:515-548.
8. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23:23-68.
9. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994; 6:414-419.
10. Anderson DE, Sharpe AH, Hafler DA. The B 7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system. Curr Opin Immunol 1999; 11:677-683.
11. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11:191-212.
12. Green JM, Noel PJ, Sperling AI, et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994; 1:501-508.
13. Szot GL, Zhou P, Rulifson I, et al. Different mechanisms of cardiac allograft rejection in wildtype and CD28-deficient mice. Am J Transplant 2001; 1:38-46.
14. Judge TA, Wu Z, Zheng XG, et al. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999; 162:1947-1951.
15. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-413.
16. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182:459-465.
17. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270:985-988.
18. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80:707-718.
19. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181:1145-1155.
20. Lenschow DJ, Zeng Y, Hathcock KS, et al. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 1995; 60:1171-1178.
21. Pearson TC, Alexander DZ, Corbascio M, et al. Analysis of the B7 costimulatory pathway in allograft rejection. Transplantation 1997; 63:1463-1469.
22. Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001; 72:377-384.
23. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257:789-792.
24. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89:11102-11105.
25. Cross AH, Girard TJ, Giacoletto KS, et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest 1995; 95:2783-2789.
26. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907-1915.
27. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159:5187-5191.
28. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94:8789-8794.
29. Greene JL, Leytze GM, Emswiler J, et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem 1996; 271:26762-26771.
30. Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1:793-801.
31. Ronchese F, Hausmann B, Hubele S, Lane P. Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+ T cells and defective antibody production in vivo. J Exp Med 1994; 179:809-817.
32. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181:1869-1874.
33. Khoury SJ, Akalin E, Chandraker A, et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995; 155:4521-4524.
34. Griggs ND, Agersborg SS, Noelle RJ, et al. The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J Exp Med 1996; 183:801-810.
35. van der Merwe PA, Bodian DL, Daenke S, et al. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997; 185:393-403.
36. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443-453. Describes the development of a fusion protein with enhanced avidity for CD28 ligands and the demonstration that it has potent immunosuppressive activity.
37. Peach RJ, Bajorath J, Brady W, et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1994; 180:2049-2058.
38. Adams AB, Shirasugi N, Durham MM, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51:265-270.
39. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174:542-550. Data from a nonhuman primate model suggest that LEA29Y can be used in a calcineurin inhibitor-free immunosuppressive regimen to prolong allograft survival.
40. Larsen CP, Charpentier B, Wekerle T, et al. Calcineurin inhibitor-free immunosuppression with belatacept (LEA29Y) in renal transplant: phase II 12-month results. Abstract #535. In: American Transplant Congress. Seattle: Marathon Multimedia; 2005.